查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931283

肽-PMO偶联物市场按治疗适应症、胜肽类型、最终用户、给药途径和产品类型划分，全球预测，2026-2032年

Peptide-PMO Conjugates Market by Therapeutic Indication, Peptide Type, End User, Route Of Administration, Product Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年胜肽-PMO 偶联物市值为 8,834 万美元，预计到 2026 年将成长至 1.0694 亿美元，复合年增长率为 15.74%，到 2032 年将达到 2.4592 亿美元。

关键市场统计数据
基准年 2025 8834万美元
预计年份：2026年 1.0694亿美元
预测年份 2032 2.4592亿美元
复合年增长率 (%) 15.74%

这篇权威的介绍清楚地向开发人员说明了胜肽-PMO偶联物的分子基础、临床应用的先决条件以及临床路径的复杂性。

胜肽-PMO偶联物融合了反义化学和基于胜肽的递送技术，旨在克服传统上限制寡核苷酸疗法的细胞内屏障。磷酰二氨酸吗啉代寡聚物（PMO）具有序列特异性功能，例如调节前体mRNA剪接和抑制翻译，而肽偶联则有助于细胞摄取、组织标靶化和核内体逃逸。该平台在系统生物分布、稳定性和靶向细胞内递送决定临床疗效的领域尤其有用。随着治疗方法的不断发展，胜肽-PMO构建体的机制优势——增强的细胞穿透性、调节的药物动力学和潜在的标靶递送能力——创造了将遗传学见解与实用治疗递送相结合的全新治疗机会。

近期的技术创新、监管变革和策略合作正在加速胜肽-PMO疗法的临床应用。

肽-PMO领域正受到多种相互作用因素的重塑，这些因素加速了转化可行性和商业性化进程。胜肽工程的进步改进了细胞穿透基序，并引入了刺激响应型设计，从而实现了基于环境的有效载荷释放；而PMO化学的创新则提高了核酸酶抗性并减少了脱靶相互作用。这些技术进步与我们对神经肌肉和神经退化性疾病生物目标的日益深入的理解相辅相成，使得更精准的外显子跳跃和剪接调控策略成为可能。这些累积效应导致了候选药物选择标准的巨大转变，而递送载体的特性如今与序列设计同等重要。

深入分析2025年美国关税将如何重塑胜肽-PMO研发领域的采购、製造地选择和投资重点。

2025年美国关税政策对复杂生物製药和寡核苷酸药物的原料采购、契约製造经济效益和资金配置产生了切实的影响。胜肽合成所需的原料、PMO骨架建造所需的专用试剂以及偶联和纯化所需的专用耗材，从关税区进口时可能面临更高的到岸成本。这些压力推高了早期研发和临床生产规模化阶段的产品总成本。为此，各机构正在重新评估筹资策略，优先考虑多元化的供应商网路和本地供应商，以降低关税风险并减少交货的不确定性。

将治疗适应症、胜肽设计范式、最终用户角色、给药途径和产品类型与开发和商业化优先事项联繫起来，提供可操作的细分洞察。

细分研究阐明了胜肽-PMO偶联物的科学机会与商业性可行性之间的交集。治疗适应症决定了临床设计和证据标准。针对肌萎缩侧索硬化症 (ALS)、贝克氏肌肉萎缩症、Duchenne氏肌肉失养症和脊髓性肌肉萎缩症 (SMA) 的项目，各自具有独特的目标组织、疾病进展时间线和终点预期。在神经肌肉适应症中，持续递送至骨骼肌和运动神经元是一项核心技术要求，临床开发路径侧重于与疾病严重程度和患者群体相适应的功能性和生物标记终点。

对美洲、欧洲、中东和非洲以及亚太地区的临床能力、监管差异和生产重点进行比较区域分析，以指南策略发展。

区域趋势将影响胜肽-PMO偶联物的临床开发路径、监管互动和生产策略。在美洲，临床试验基础设施和投资资本集中在拥有成熟神经肌肉和严重疾病网络的地区，有助于加快患者招募，并能获得专门的临床终点和註册资讯。监管互动通常着重于针对存在未满足医疗需求的严重疾病的快速审批途径，而完善的专科医疗管道也有利于商业性市场进入计划的实施。

公司层面的优势（智慧财产权、平台技术、策略联盟、製造伙伴关係）如何塑造胜肽-PMO开发中的竞争优势与合作潜力

该领域的竞争不在于任何单一要素的优越性，而是整合胜肽设计、寡核苷酸化学、生产规模化和临床开发等方面的专业知识。主要企业透过将深厚的反义寡核苷酸或PMO经验与胜肽递送技术结合，同时投资强大的CMC平台，以支援可重复的偶联和分析控制，从而脱颖而出。胜肽专家和反义寡核苷酸开发人员之间的策略联盟结合了互补的科学优势，并在临床前检验的关键节点上共用风险，从而加速候选药物的研发。

为经营团队和研发领导者提供实际有效的建议，以降低风险、优化伙伴关係并加速胜肽类药物-PMO计画的临床和商业化准备。

根据整合胜肽设计、PMO化学和给药途径的目标，量身订做早期开发策略。优先考虑能够反映目标组织生物学特性的临床前模型，这些模型应包含剪接调控和相关的标靶结合生物标记。早期投资转化生物标记和自然史数据可以显着缩短阐明作用机制的时间，并增强临床研究人员和支付者的信心。同时，采用模组化的CMC开发方案，以便在不影响临床交付时间表的情况下，迭代优化偶联过程。

以清晰且可重复的调查方法为策略结论提供支撑，该方法整合了文献综述、专家访谈、监管分析和三角检验。

本研究综合分析了同行评审文献、监管申报文件、临床试验註册资讯以及与胜肽化学、反义核酸治疗药物、临床开发和生产领域专家的访谈结果。证据综合优先考虑与神经肌肉疾病和神经退化性疾病相关的递送、生物分布、安全性和临床终点直接相关的研究和监管文件。关键的定性资讯则透过与转化科学家、临床研究人员、CMC专家以及在偶联寡核苷酸计画方面拥有直接经验的高阶主管进行结构化访谈而获得。

策略结论：透过优先考虑转化检验、生产准备和合作模式，加速胜肽类药物的临床应用。

胜肽-PMO偶联物处于靶向寡核苷酸活性和增强细胞内递送的交汇点，为解决传统上难以攻克的递送难题提供了一条切实可行的途径。此领域的成功取决于胜肽设计、PMO设计、分析严谨性和供应链韧性等方面的协调执行。相关人员应着重提供可重复的转换证据，确保递送创新技术的强大智慧财产权，并建立能够共用技术风险、加速临床检验的伙伴关係。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗适应症分類的胜肽-PMO偶联物市场

  • 肌萎缩侧索硬化症
  • 贝克氏肌肉萎缩症
  • Duchenne氏肌肉失养症
  • 脊髓性肌肉萎缩症

9. 依胜肽类型分類的胜肽-PMO偶联物市场

  • 细胞渗透性
    • 来自 Antennapedia
    • 塔特衍生
    • 源自运输
  • 刺激反应性
    • 酶响应
    • pH响应
    • 温度响应性
  • 标靶化投放
    • 抗体偶联型
    • 受体特异性

第十章 依最终用户分類的胜肽-PMO偶联物市场

  • 学术研究机构
  • 生技公司
  • 合约研究机构
  • 製药公司

11. 依给药途径分類的胜肽-PMO偶联物市场

  • 肌肉内注射
  • 静脉注射
  • 皮下注射

12. 胜肽-PMO偶联物市场（依产品类型划分）

  • 双链
  • 单链

13. 各地区胜肽-PMO偶联物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 胜肽-PMO偶联物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国肽-PMO偶联物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国胜肽-PMO偶联物市场

17. 中国肽-PMO偶联物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • AmbioPharm, Inc.
  • Avidity Biosciences, Inc.
  • Bachem Holding AG
  • Bio-Synthesis, Inc.
  • Bio-Techne Corporation
  • Creative Biogene Corporation
  • Danaher Corporation
  • Entrada Therapeutics, Inc.
  • Gene Tools, LLC
  • GenScript Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • PeptiDream Inc.
  • PolyPeptide Group AG
  • QIAGEN NV
  • Sarepta Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-7B550E008E07

The Peptide-PMO Conjugates Market was valued at USD 88.34 million in 2025 and is projected to grow to USD 106.94 million in 2026, with a CAGR of 15.74%, reaching USD 245.92 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 88.34 million
Estimated Year [2026] USD 106.94 million
Forecast Year [2032] USD 245.92 million
CAGR (%) 15.74%

An authoritative primer on peptide-PMO conjugates that clarifies the molecular rationale, translational prerequisites, and clinical pathway complexities for developers

Peptide-PMO conjugates represent a convergence of antisense chemistry and peptide-enabled delivery, designed to address intracellular barriers that have historically limited oligonucleotide therapies. Phosphorodiamidate morpholino oligomers (PMOs) carry sequence-specific capacity to modulate pre-mRNA splicing or inhibit translation, and conjugation to peptides enhances cellular uptake, tissue targeting, and endosomal escape. The platform is particularly relevant where systemic biodistribution, stability, and targeted intracellular delivery determine clinical efficacy. As modalities evolve, the mechanistic advantages of peptide-PMO constructs-improved cellular penetration, modulated pharmacokinetics, and potential for targeted delivery-create new therapeutic opportunities that bridge genetic understanding with practical therapeutic delivery.

Translational success demands rigorous alignment between peptide chemistry, PMO design, and route of administration. Intramuscular or intravenous delivery choices alter biodistribution and immunogenic exposure, while peptide type-whether cell penetrating, stimuli responsive, or targeted-shapes intracellular trafficking and specificity. Simultaneously, therapeutic indication informs acceptable safety margins and clinical endpoints; for example, indications for neuromuscular disorders require durable tissue penetration of skeletal muscle and motor neuron compartments. Consequently, development programs that integrate robust preclinical pharmacology, scalable conjugation manufacturing, and regulatory pathway planning will be positioned to advance clinical candidates more effectively.

This introduction frames why peptide-PMO conjugates are attracting multidisciplinary investment from chemistry, biology, and clinical development teams and sets the stage for deeper examination of market-relevant trends, segmentation dynamics, regulatory pressures, and actionable strategic priorities.

How recent technological innovations, regulatory evolution, and strategic partnerships are jointly accelerating translation of peptide-PMO therapeutics into clinical practice

The peptide-PMO landscape is being reshaped by several intersecting forces that accelerate translational feasibility and commercial interest. Advances in peptide engineering have improved cell-penetrating motifs and introduced stimuli-responsive designs that permit context-dependent payload release, while innovations in PMO chemistry have extended nuclease resistance and reduced off-target interactions. These technology advances are occurring in parallel with a richer understanding of target biology for neuromuscular and neurodegenerative disorders, enabling more precise exon-skipping and splice-modulation strategies. The cumulative effect is a step-change in candidate selection criteria where delivery vector properties are as critical as sequence design.

Regulatory pathways and payer expectations are evolving to accommodate novel oligonucleotide conjugates, emphasizing robust safety pharmacology, biodistribution data, and biomarker-driven proof of mechanism. At the same time, manufacturing scale-up has moved from boutique GMP efforts toward platform-enabled production models that emphasize reproducibility and cost controls, driven by collaborations between biotech developers and specialized contract manufacturers. Commercially, strategic partnerships and licensing arrangements are becoming the norm to combine peptide delivery know-how with antisense therapeutic expertise. These partnerships accelerate the de-risking of preclinical programs by aligning complementary capabilities.

Collectively, these shifts favor integrated programs that harmonize discovery, CMC, regulatory strategy, and commercial planning from early development. Organizations that adapt to this integrated model will capture efficiency advantages and shorten timelines from candidate validation to clinical proof of concept.

Detailed analysis of how 2025 United States tariff measures are reshaping procurement, manufacturing location decisions, and investment priorities across peptide-PMO development

Tariff measures introduced in the United States in 2025 have created tangible ripple effects across pharmaceutical ingredient sourcing, contract manufacturing economics, and capital allocation for complex biologic and oligonucleotide modalities. Raw materials used in peptide synthesis, specialty reagents for PMO backbone construction, and specialized consumables for conjugation and purification may be subject to increased landed costs when imported from tariff-affected jurisdictions. These pressures elevate the total cost of goods for early-stage development activities and for scaled clinical manufacturing runs. In response, organizations are reassessing procurement strategies to prioritize diversified vendor networks and near-shore suppliers to mitigate customs exposure and reduce delivery lead-time uncertainty.

Beyond direct procurement cost impacts, tariff-driven shifts influence strategic choices around manufacturing location and capacity investment. Some developers are accelerating qualification of domestic contract manufacturing partners to insulate critical supply chains from cross-border tariff volatility. Where feasible, vertical integration or multi-supplier redundancy is being implemented to preserve continuity for clinical programs with narrow manufacturing windows. Investors and corporate finance teams are also factoring tariff uncertainty into capital allocation models, prioritizing programs with clearer supply chain visibility or alternative sourcing options.

Regulatory compliance and customs classification complexity have increased administrative overhead for organizations with global procurement footprints, requiring enhanced tariff engineering and customs expertise. Consequently, development teams must coordinate more closely with procurement, legal, and regulatory affairs to maintain project timelines. The net effect is a strategic rebalancing that emphasizes supply chain resilience, supplier qualification diversity, and contractual protections to safeguard clinical progress and protect margins under tariff uncertainty.

Actionable segmentation insights that map therapeutic indications, peptide design paradigms, end-user roles, administration routes, and product types to development and commercialization priorities

Segmentation clarifies where scientific opportunity and commercial viability intersect for peptide-PMO conjugates. Therapeutic indication drives clinical design and evidence standards; programs aimed at Amyotrophic Lateral Sclerosis, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Spinal Muscular Atrophy each present unique target tissues, progression timelines, and endpoint expectations. For neuromuscular indications, durable delivery to skeletal muscle and motor neurons is a core technical requirement, and the clinical development pathway emphasizes functional and biomarker outcomes appropriate to disease severity and patient populations.

Peptide type defines delivery strategy and intracellular fate. Cell penetrating peptides remain central for broad intracellular uptake and include derivatives such as Antennapedia, Tat, and Transportan architectures, each with distinct uptake kinetics and safety profiles. Stimuli-responsive constructs introduce conditional release mechanisms-enzyme-responsive, pH-responsive, and temperature-responsive designs tailor payload activation to pathological microenvironments. Targeted delivery approaches focus on receptor engagement or antibody conjugation to improve tissue selectivity and decrease off-target exposure. These peptide classifications inform conjugation chemistry, dosing frequency, and immunogenicity considerations.

End user segmentation affects development timelines and collaboration models. Academic and research institutes typically drive early discovery and exploratory pharmacology, biotechnology companies advance translational proof of concept and investor-driven value creation, contract research organizations offer scalable preclinical and clinical execution capabilities, and pharmaceutical companies provide commercialization infrastructure and regulatory experience. Route of administration-intramuscular, intravenous, and subcutaneous-modulates systemic exposure, patient acceptability, and clinical site requirements. Product type differences between conjugated complexes, double stranded, and single stranded constructs influence manufacturing complexity, stability profiles, and analytical method development. Understanding these intersecting segments enables prioritization of R&D investment, selection of appropriate development partners, and alignment of clinical strategies with payer and regulatory expectations.

Comparative regional analysis of clinical capacity, regulatory nuance, and manufacturing priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific to guide strategic deployment

Regional dynamics shape clinical development pathways, regulatory interactions, and manufacturing strategies for peptide-PMO conjugates. In the Americas, clinical trial infrastructure and investor capital are concentrated in hubs with established neuromuscular and rare disease networks, which accelerates patient recruitment and provides access to specialized clinical endpoints and registries. Regulatory engagement often emphasizes expedited pathways for severe conditions with unmet need, and commercial market access planning benefits from well-developed specialty care channels.

Europe, Middle East & Africa presents a heterogeneous environment with variable regulatory expectations and reimbursement mechanisms. Several European regulatory authorities emphasize robust comparative effectiveness and health technology assessment evidence, shaping trial design and evidence generation strategies. Regional collaboration for rare disease registries and cross-border clinical networks can facilitate multi-country studies, but sponsors must plan for divergent reimbursement timelines and pricing pressures across jurisdictions.

Asia-Pacific presents rapid growth in clinical research capacity, an expanding pool of manufacturing talent, and diverse regulatory pathways that range from mature frameworks to rapidly evolving systems. Several countries in the region are investing in biotech manufacturing infrastructure and life sciences R&D incentives, creating attractive options for clinical manufacturing and regional trial execution. Each region's strengths inform strategic decisions about where to site trials, establish manufacturing partnerships, and prioritize market-entry sequencing to optimize clinical timelines and long-term access.

How company-level strengths in IP, platform engineering, strategic alliances, and manufacturing partnerships shape competitive advantage and partnership potential in peptide-PMO development

Competitive dynamics in this space are less about single-factor dominance and more about integrative capabilities across peptide design, oligonucleotide chemistry, manufacturing scale-up, and clinical development expertise. Leading organizations distinguish themselves by combining deep antisense or PMO experience with peptide delivery know-how, while also investing in robust CMC platforms that support reproducible conjugation and analytical control. Strategic alliances between peptide specialists and antisense developers accelerate candidate progress by pairing complementary scientific strengths and sharing risk across preclinical validation milestones.

Intellectual property around novel peptide motifs, conjugation chemistries, and delivery platforms is a material differentiator. Companies with well-constructed patent estates around specific cell-penetrating sequences or stimuli-responsive linkers can secure competitive moats that encourage licensing and partnership opportunities. At the same time, cross-licensing and co-development agreements have emerged as pragmatic approaches to bring complex candidates into clinical testing more quickly while leveraging established commercial channels.

Operationally, companies that have established relationships with specialized contract development and manufacturing organizations and that demonstrate clear scale-up pathways for conjugated oligonucleotides reduce execution risk. Additionally, firms that invest in translational biomarker programs and robust natural history studies enhance their ability to design efficient clinical trials and to engage payers with mechanistic evidence. The most successful organizations balance proprietary science with collaborative business models to optimize both innovation velocity and commercial feasibility.

High-impact, pragmatic recommendations for executives and R&D leaders to de-risk peptide-PMO programs, optimize partnerships, and accelerate clinical and commercial readiness

Align early development strategies around integrative objectives that combine peptide design, PMO chemistry, and route-of-administration decisions. Prioritize preclinical models that reflect target tissue biology and that include relevant biomarkers of splice modulation or target engagement. Early investment in translational biomarkers and natural history data can materially shorten time to clear proof-of-mechanism signals and increase confidence among clinical investigators and payers. Concurrently, adopt modular CMC development plans that allow iterative optimization of conjugation processes without disrupting clinical supply timelines.

Diversify supplier networks and qualify multiple manufacturing partners to mitigate tariff and logistics risks, and consider near-shore or regional manufacturing options to improve supply resilience. Seek strategic partnerships that pair peptide delivery expertise with antisense development capabilities to share technical risk and to accelerate clinical candidate advancement. Negotiate licensing and co-development terms that preserve sufficient upside while ensuring access to essential platform IP and manufacturing know-how.

Engage proactively with regulatory authorities to validate nonclinical packages, biodistribution expectations, and safety monitoring frameworks. Incorporate payers and HTA considerations early by documenting meaningful clinical benefit and health economics implications of targeted delivery approaches. Finally, build organizational capabilities in analytic method development and stability testing specific to conjugated oligonucleotides to de-risk late-stage development and support confident commercialization readiness.

A clear, reproducible research methodology that integrates literature review, expert interviews, regulatory analysis, and triangulated validation to underpin strategic conclusions

This research synthesized evidence from a comprehensive review of peer-reviewed literature, regulatory filings, clinical trial registries, and primary interviews with domain experts across peptide chemistry, antisense therapeutics, clinical development, and manufacturing. Evidence synthesis prioritized studies and regulatory documents that directly address delivery, biodistribution, safety, and clinical endpoints relevant to neuromuscular and neurodegenerative indications. Primary qualitative input was obtained through structured interviews with translational scientists, clinical investigators, CMC specialists, and senior executives who have direct experience with conjugated oligonucleotide programs.

Analytic rigor was maintained by triangulating qualitative inputs with published pharmacology data and with publicly available regulatory guidance. The methodology incorporated a gap analysis to identify where preclinical models, assay standardization, or manufacturing controls required additional focus. Where possible, findings were validated against multiple expert perspectives to reduce single-source bias and to ensure practical relevance to program execution. Assumptions used to derive strategic implications were explicitly documented and stress-tested through scenario analysis that considered supply chain disruption, regulatory variation across regions, and differing commercialization pathways.

This methodological approach produces insights that are actionable for developers and investors by combining empirical evidence with practitioner-informed judgment while maintaining transparency about sources and the limitations of available data.

A strategic conclusion that prioritizes translational validation, manufacturing readiness, and collaborative models to accelerate peptide-PMO clinical impact

Peptide-PMO conjugates occupy a promising intersection of targeted oligonucleotide activity and enhanced intracellular delivery, offering tangible routes to address historically intractable delivery challenges. Success in this field hinges on coordinated execution across peptide engineering, PMO design, analytical rigor, and supply chain resilience. Stakeholders should focus on delivering reproducible translational evidence, securing robust IP around delivery innovations, and building collaborative partnerships that accelerate clinical validation while sharing technical risk.

Immediate priorities for developers include establishing translational biomarkers, qualifying manufacturing partners with conjugation expertise, and proactively addressing regional regulatory nuances to support multi-jurisdictional development strategies. For investors and corporate strategy teams, the emphasis should be on backing integrated platforms with clear CMC pathways, validated delivery mechanisms, and demonstrable clinical proof of concept in target indications. By concentrating on these pragmatic levers-translational validation, manufacturing readiness, and strategic collaboration-organizations can move promising peptide-PMO candidates toward meaningful clinical impact with minimized execution risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide-PMO Conjugates Market, by Therapeutic Indication

  • 8.1. Amyotrophic Lateral Sclerosis
  • 8.2. Becker Muscular Dystrophy
  • 8.3. Duchenne Muscular Dystrophy
  • 8.4. Spinal Muscular Atrophy

9. Peptide-PMO Conjugates Market, by Peptide Type

  • 9.1. Cell Penetrating
    • 9.1.1. Antennapedia Derived
    • 9.1.2. Tat Derived
    • 9.1.3. Transportan Derived
  • 9.2. Stimuli Responsive
    • 9.2.1. Enzyme Responsive
    • 9.2.2. PH Responsive
    • 9.2.3. Temperature Responsive
  • 9.3. Targeted Delivery
    • 9.3.1. Antibody Conjugated
    • 9.3.2. Receptor Specific

10. Peptide-PMO Conjugates Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Peptide-PMO Conjugates Market, by Route Of Administration

  • 11.1. Intramuscular
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Peptide-PMO Conjugates Market, by Product Type

  • 12.1. Double Stranded
  • 12.2. Single Stranded

13. Peptide-PMO Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide-PMO Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide-PMO Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide-PMO Conjugates Market

17. China Peptide-PMO Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. AmbioPharm, Inc.
  • 18.7. Avidity Biosciences, Inc.
  • 18.8. Bachem Holding AG
  • 18.9. Bio-Synthesis, Inc.
  • 18.10. Bio-Techne Corporation
  • 18.11. Creative Biogene Corporation
  • 18.12. Danaher Corporation
  • 18.13. Entrada Therapeutics, Inc.
  • 18.14. Gene Tools, LLC
  • 18.15. GenScript Biotech Corporation
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. Merck KGaA
  • 18.18. Moderna, Inc.
  • 18.19. Novartis AG
  • 18.20. PeptiDream Inc.
  • 18.21. PolyPeptide Group AG
  • 18.22. QIAGEN N.V.
  • 18.23. Sarepta Therapeutics, Inc.
  • 18.24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE-PMO CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BECKER MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTENNAPEDIA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TAT DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TRANSPORTAN DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ENZYME RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PH RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TEMPERATURE RESPONSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ANTIBODY CONJUGATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY RECEPTOR SPECIFIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY DOUBLE STRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SINGLE STRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 169. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PEPTIDE-PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY CELL PENETRATING, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY STIMULI RESPONSIVE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY TARGETED DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA PEPTIDE-PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)